Propanc Biopharma, Inc.
PPCB· Nasdaq
Filed Sep 30, 2024 · 10-K · 92 days after period end · 0001493152-24-038815
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$358.58K | -$748.04K | -$904.77K | -$779.02K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Sep 30, 2024 · 92 d after period end